Nonspecific oral medications versus anti–calcitonin gene‐related peptide monoclonal antibodies for migraine: A systematic review and meta‐analysis of randomized controlled trials

降钙素基因相关肽 偏头痛 荟萃分析 医学 降钙素 单克隆抗体 随机对照试验 内科学 单克隆 药理学 抗体 免疫学 神经肽 受体
作者
Jennifer Robblee,Sameh M. Hakim,John Reynolds,Teshamae Monteith,Niushen Zhang,Meredith Barad
出处
期刊:Headache [Wiley]
卷期号:64 (5): 547-572 被引量:2
标识
DOI:10.1111/head.14693
摘要

Abstract Objective To compare calcitonin gene–related peptide monoclonal antibodies (CGRP mAbs) versus nonspecific oral migraine preventives (NOEPs). Background Insurers mandate step therapy with NOEPs before approving CGRP mAbs. Methods Databases were searched for class I or II randomized controlled trials (RCTs) comparing CGRP mAbs or NOEPs versus placebo for migraine prevention in adults. The primary outcome measure was monthly migraine days (MMD) or moderate to severe headache days. Results Twelve RCTs for CGRP mAbs, 5 RCTs for topiramate, and 3 RCTs for divalproex were included in the meta‐analysis. There was high certainty that CGRP mAbs are more effective than placebo, with weighted mean difference (WMD; 95% confidence interval) of −1.64 (−1.99 to −1.28) MMD, which is compatible with small effect size (Cohen's d −0.25 [−0.34 to −0.16]). Certainty of evidence that topiramate or divalproex is more effective than placebo was very low and low, respectively (WMD −1.45 [−1.52 to −1.38] and −1.65 [−2.30 to −1.00], respectively; Cohen's d −1.25 [−2.47 to −0.03] and −0.48 [−0.67 to −0.29], respectively). Trial sequential analysis showed that information size was adequate and that CGRP mAbs had clear benefit versus placebo. Network meta‐analysis showed no statistically significant difference between CGRP mAbs and topiramate (WMD −0.19 [−0.56 to 0.17]) or divalproex (0.01 [−0.73 to 0.75]). No significant difference was seen between topiramate or divalproex (0.21 [−0.45 to 0.86]). Conclusions There is high certainty that CGRP mAbs are more effective than placebo, but the effect size is small. When feasible, CGRP mAbs may be prescribed as first‐line preventives; topiramate or divalproex could be as effective but are less well tolerated. The findings of this study support the recently published 2024 position of the American Headache Society on the use of CGRP mAbs as the first‐line treatment.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
ZD完成签到 ,获得积分10
5秒前
7秒前
英姑应助普鲁卡因采纳,获得10
10秒前
冰糕发布了新的文献求助10
12秒前
BettyNie完成签到 ,获得积分10
14秒前
优雅的平安完成签到 ,获得积分10
14秒前
冰糕完成签到,获得积分10
19秒前
21秒前
852应助完犊子采纳,获得10
25秒前
ruochenzu发布了新的文献求助10
26秒前
不想洗碗完成签到 ,获得积分10
28秒前
const完成签到,获得积分10
32秒前
hjx完成签到 ,获得积分10
32秒前
稳重的尔安完成签到,获得积分10
34秒前
量子星尘发布了新的文献求助10
35秒前
缓慢的饼干完成签到 ,获得积分10
35秒前
saturn完成签到 ,获得积分10
35秒前
金桔希子完成签到,获得积分10
36秒前
Breeze完成签到 ,获得积分10
36秒前
36秒前
昏睡的眼神完成签到 ,获得积分10
37秒前
文心同学完成签到,获得积分0
38秒前
demom完成签到 ,获得积分10
40秒前
duckspy完成签到 ,获得积分10
40秒前
完犊子发布了新的文献求助10
42秒前
普鲁卡因发布了新的文献求助30
43秒前
chenkj完成签到,获得积分10
45秒前
EricSai完成签到,获得积分10
45秒前
ikun完成签到,获得积分10
45秒前
李李发布了新的文献求助10
45秒前
章鱼小丸子完成签到 ,获得积分10
45秒前
byby完成签到,获得积分10
47秒前
THEO完成签到 ,获得积分10
48秒前
李健的小迷弟应助完犊子采纳,获得10
49秒前
50秒前
乐观的问兰完成签到 ,获得积分10
51秒前
书生完成签到,获得积分10
51秒前
朱佳宁完成签到 ,获得积分10
52秒前
Master完成签到 ,获得积分10
53秒前
怕孤独的香菇完成签到 ,获得积分10
53秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038112
求助须知:如何正确求助?哪些是违规求助? 3575788
关于积分的说明 11373801
捐赠科研通 3305604
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022